Monday June 10, 2019 |
10:00 | Optional Excursions |
|
15:00 | Registration |
|
17:30 | Opening of the Symposium & Welcome Address |
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| Session Chair |
Prof. Katarzyna KIEC-KONONOWICZ (JAGIELLONIAN UNIVERSITY, Krakow, Poland) |
17:45 | Derivatives of 1,3,5-triazine as a New Trend in the Search for the 5-HT6 Receptor Ligands with Therapeutic Perspectives (PL01) |
Prof. Jadwiga HANDZLIK (MEDICAL COLLEGE OF JAGIELLONIAN UNIVERSITY, Krakow, Poland) |
18:30 | Welcome Reception |
|
Tuesday June 11, 2019 |
08:00 | Registration |
|
| Matrix Metallo-Proteinases |
|
| Session Chair |
Prof. Krzysztof JOZWIAK (MEDICAL UNIVERSITY OF LUBLIN, Lublin, Poland) |
09:00 | Libraries of Fluorogenic Substrates with Natural and Unnatural Amino Acids as a Tool in Design of Active and Specific Probes for Investigation of Proteolytic Enzymes (IL01) |
Prof. Marcin DRAG (WROCLAV UNIVERSITY OF TECHNOLOGY, Wroclaw, Poland) |
09:30 | MMP-9 at the Synapse in the Brain and Mind (IL02) |
Prof. Leszek KACZMAREK (NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Warsaw, Poland) |
10:00 | Metalloproteinase Cleavage Control of Interferon Alpha and Gamma Dampens Inflammation and Anti-Viral Immunity (IL03) |
Prof. Christopher OVERALL (UNIVERSITY OF BRITISH COLUMBIA, Vancouver, Canada) |
10:30 | Coffee Break and Exhibition |
|
| Genomics in Drug Discovery : Roles for Chemistry |
|
| Session Chair |
Prof. Terry MOORE (UNIVERSITY OF ILLINOIS, Chicago, IL, United States) |
11:00 | Designing Synthetic Gene Regulators (SynGR) (IL04) |
Prof. Aseem ANSARI (UNIVERSITY OF WISCONSIN-MADISON, Madison, United States) |
11:30 | Exploring Bacterial Genomes for Natural Product Discovery and Development (IL05) |
Prof. Alessandra S. EUSTAQUIO (UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, United States) |
12:00 | Integrative Screening Identifies a Novel Node in the Oncogenic YAP/HIPPO Pathway (IL06) |
Dr Mathias FREDERIKSEN (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH (NIBR), Basel, Switzerland) |
12:30 | Lunch and Exhibition |
|
| Advances in Protein Degradation Technologies |
|
| Session Chair |
Prof. Daniel HARKI (UNIVERSITY OF MINNESOTA, Minneapolis, MN, United States) |
14:00 | Targeted Protein Degradation with Small Molecules: how PROTACs Work (IL07) |
Prof. Alessio CIULLI (UNIVERSITY OF DUNDEE, Dundee, United Kingdom) |
14:30 | The Ubiquitin System (IL08) |
Prof. Huib OVAA (LEIDEN UNIVERSITY MEDICAL CENTER, Leiden, The Netherlands) |
15:00 | Small-Molecule Modulation of Cereblon Protein Level (OC01) |
Dr Christian STEINEBACH (UNIVERSITY OF BONN, Bonn, Germany) |
15:15 | Drugging Challenging E3 Ligases: A Novel Multidisciplinary Approach to Identify Small-Molecules that Bind FBW7 (OC02) |
Ms Miriam MARTINEZ CARTRO (UNIVERSITY OF BARCELONA, Barcelona, Spain) |
15:30 | Coffee Break and Exhibition |
|
| Session Chair |
Prof. Andrzej BOJARSKI (INSTITUTE OF PHARMACOLOGY POLISH ACADEMY OF SCIENCES, Krakow, Poland) |
16:00 | Systems Pharmacology Links GPCRs with Retinal Degenerative Disorders (PL02) |
Prof. Krzysztof PALCZEWSKI (CASE WESTERN RESERVE UNIVERSITY, Cleveland, United States) |
16:45 | First Time Disclosure The Discovery of LML134, a Histamine H3 Receptor Inverse Agonist for the Clinical Treatment of Excessive Sleep Disorders (IL09) |
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
17:15 | Poster Session 1 (Posters with odd numbers) |
|
18:15 | City Tour |
|
Wednesday June 12, 2019 |
08:59 | GPCRs: a Discovery Powerhouse |
|
| Session Chair |
Dr Yves P. AUBERSON (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
09:00 | G Protein-Coupled Receptors: the Structural Basis for their Pharmacology (IL10) |
Dr Chris TATE (MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge, United Kingdom) |
09:30 | Design of Orexin 1 Receptor Selective Antagonists (IL11) |
Dr Uta LESSEL (BOEHRINGER INGELHEIM PHARMA GMBH & CO KG, Biberach an der Riss, Germany) |
10:00 | Next Generation GPR119 Agonists as Potential Treatment for Cardiometabolic Diseases (IL12) |
Dr Lothar SCHWINK (SANOFI, Frankfurt Am Main, Germany) |
10:30 | Coffee Break and Exhibition |
|
| Specific and Multi-Targeted Drugs
|
|
| Session Chair |
Prof. Andrzej BOJARSKI (INSTITUTE OF PHARMACOLOGY POLISH ACADEMY OF SCIENCES, Krakow, Poland) |
11:00 | Charting New Paths in Multi-Target Drug Discovery for Alzheimer’s Disease (IL13) |
Prof. Maria Laura BOLOGNESI (UNIVERSITY OF BOLOGNA, Bologna, Italy) |
11:30 | Multiple Targeting - The Histamine H3 Receptor Pharmacophore as Central Element (IL14) |
Prof. Holger STARK (HEINRICH HEINE UNIVERSITY DÜSSELDORF, Duesseldorf, Germany) |
12:00 | Chemical Biology for Drug Discovery: A Click and Play Approach Exemplified by ERK1/2 Probes (OC03) |
Dr Charlotte GRIFFITHS-JONES (ASTEX PHARMACEUTICALS, Cambridge, United Kingdom) |
12:15 | Identification and in-vivo Efficacy Studies of a Nicotinamide Derivative as Novel NNMT Inhibitor (OC04) |
Dr Sven RUF (SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany) |
12:30 | Lunch and Exhibition |
|
| Opioid, Pain, Endo-Cannabinoid |
|
| Session Chair |
Prof. Katarzyna KIEC-KONONOWICZ (JAGIELLONIAN UNIVERSITY, Krakow, Poland) |
14:00 | Cannabinoid Receptor Type 2 Modulation to Improve Outcomes for Cartilage Repair in the Osteoarthritic Joint (IL15) |
Prof. Katarzyna STAROWICZ-BUBAK (INSTITUTE OF PHARMACOLOGY, POLISH ACADEMY OF SCIENCES, Krakow, Poland) |
14:30 | Potential of Natural Cannabinoids and Synthetic Cannabinoids in Neuroprotection (IL16) |
Prof. Rafael FRANCO (UNIVERSITY OF BARCELONA, Barcelona, Spain) |
15:00 | Discovery of Best in-class, Novel, Selective, Potent and Peripheral FLT3 Inhibitors, a New Way to Treat Neuropathic Pain (OC05) |
Dr Dominique SURLERAUX (BCI PHARMA, Liège, Belgium) |
15:15 | The Discovery and Development of the Clinical FAAH Inhibitor JNJ-42165279 (OC06) |
Prof. James BREITENBUCHER (UNIVERSITY OF CALIFORNIA SAN FRANCISCO, San Francisco, United States) |
15:30 | Coffee Break and Exhibition |
|
| Session Chair |
Prof. Terry MOORE (UNIVERSITY OF ILLINOIS, Chicago, IL, United States) |
16:00 | Next Generation Pain Therapeutics for the Opioid Crisis: Design of Bifunctional Nociceptin/Mu Opioid GPCR Ligands as non-Addicting Analgesics (PL03) |
Dr Nurulain ZAVERI (ASTRAEA THERAPEUTICS, Mountain View, United States) |
16:45 | Pharma Research Highlights in Poland |
|
16:45 | Discovery of OAT-2068 - A Potent, Selective, Orally Bioavailable Inhibitor of Mouse Chitotriosidase and its In Vivo Activity in the Bleomycin-Induced Pulmonary Fibrosis Model in Mice (OC07) |
Dr Agnieszka BARTOSZEWICZ (MOLECURE S.A, Warszawa, Poland) |
17:00 | DPD-inspired Small Heterocyclic Libraries Characterized as Novel LsrK Kinase Inhibitors: an Opportunity to Fight Antimicrobial Resistance (OC08) |
Dr Anna KARAWAJCZYK (SELVITA, Krakow, Poland) |
17:15 | Poster Session 2 (Posters with even numbers) |
|
18:15 | End of Poster Session |
|
20:00 | Symposium Banquet |
|
Thursday June 13, 2019 |
| Chemical Biology Tools & Target Engagement Technologies |
|
| Session Chair |
Prof. Edgars SUNA (LATVIAN INSTITUTE OF ORGANIC SYNTHESIS, Riga, Latvia) |
09:00 | Protein-Ligand Interactions: How Medicinal Chemistry Contributes to the Understanding of Molecular Recognition (IL17) |
Dr Marc NAZARE (FMP, Berlin, Germany) |
09:30 | Adventures in Targeting Protein Lipdation: Breaking Drug Resistance Using Fragment Deconstruction and Chemical Biology (IL18) |
Prof. Edward TATE (IMPERIAL COLLEGE LONDON, London, United Kingdom) |
10:00 | Tankyrase Inhibitors : Evidence for Therapeutic Potential in Immuno-Oncology |
Dr Luc VAN HIJFTE (MERCACHEMSYNCOM, Nijmegen, The Netherlands) |
10:30 | Coffee Break and Exhibition |
|
| Targeted Covalent Inhibitors |
|
| Session Chair |
Dr. Anders KARLÉN (UPPSALA UNIVERSITY, Uppsala, Sweden) |
11:00 | Safety First: Covalent Inhibitors from a Safety Perspective (IL20) |
Dr Mickael MOGEMARK (ASTRAZENECA, Mölndal, Sweden) |
11:30 | Adventures in Functional Assignment and Inhibition of Metallo-Enzymes (IL21) |
Prof. Christopher J. SCHOFIELD (UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
12:00 | Mining the Protein Kinase Cysteinome (IL22) |
Dr Tjeerd BARF (ACERTA PHARMA BV, Oss, The Netherlands) |
12:30 | Lunch and Exhibition |
|
| Adding AI to the Drug Discovery Tool Box |
|
| Session Chair |
Dr Carolyn DZIERBA (BRISTOL-MYERS SQUIBB, Cambridge, MA, United States) |
14:00 | Learning the Art of Chemical Synthesis with Deep Neural Networks and Discipline Scale Data (IL23) |
Prof. Mark WALLER (UNIVERSITY OF WOLLONGONG, Wollongong, Australia) |
14:30 | Applications of Artificial Intelligence in Drug Discovery – Separating Hype From Utility (IL24) |
Dr Patrick WALTERS (RELAY THERAPEUTICS, Cambridge, MA, United States) |
15:00 | Augmented Intelligence for Compound Design (OC09) |
Dr Michal WARCHOL (ARDIGEN, Krakow, Poland) |
15:15 | Capturing and Applying Knowledge to Guide Compound Optimisation (OC10) |
Dr Nick FOSTER (OPTIBRIUM, Litlington, United Kingdom) |
15:30 | Closing Remarks |
|